![]() ![]() Mezu, R.N., designee of State Superintendent of Schools Jessica K. Sexton, designee of Secretary of State Police Alicia L. Pedersen, designee of Secretary of Human Services Jennifer Maehr, M.D., designee of Secretary of Juvenile Services Sgt. Choo, M.D., designee of Secretary of Health Katie R. Latoya BatesĮx officio: Karen Anderson-Scott, Esq., designee of Attorney General Shelly S. Representing State Infant Death Syndrome Information & Counseling Program: A. Roberts Jennifer Anne Thomas Anntinette D. Richard Lichenstein, M.D., Chair (chosen by Team) Laura Herrera Scott, M.D., Secretary of Health (appointed by Governor with Senate advice & consent) (410) 767-4639 ORGANIZATIONAL STRUCTURE OFFICE OF SECRETARYįY2021 appropriation: $14,474,730 authorized positions: 121 Senior Prescription Drug Assistance Program 1-80 (toll free).Respiratory Syncytial Virus Infection (RSV).Pharmacy Assistance (Medicaid): 1-80 (toll free).Opioid & other substance abuse disorders 1-80 (toll free).Medical Assistance (Medicaid): 1-80 (toll free).Health Improvement Process, State (SHIP).Health Care Health Hotlines Health Hot Topics: 1-86 (toll free, 24-hour-a-day).O'Conor State Office Building, 201 West Preston St., Baltimore, Maryland, October 2019. Web: (health & support services - Maryland Access Point) Grant, Assistant Secretary for Health Policy (410) 767-6481 Vacancy, Assistant Secretary for Customer Experience (443) 478-6397 Nilesh Kalyanaraman, M.D., Deputy Secretary, Public Health Services (410) 767-6525 Mroz, Deputy Secretary, Operations (410) 767-6821 Moran, Dr.P.H., Deputy Secretary, Health Care Financing & Medicaid Director (410) 767-5343īryan I. Simons, Deputy Secretary, Developmental Disabilities (410) 767-5607 Vacancy, Deputy Secretary, Behavioral Health (410) 402-8452īernard A. ).Health, Maryland Department of MARYLAND DEPARTMENT OF HEALTH Laura Herrera Scott, M.D., Secretary of Health (410) 767-4639 (Funded by Amarin Pharma REDUCE-IT number, NCT01492361. ![]() Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06).Īmong patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75 95% confidence interval, 0.68 to 0.83 P<0.001) the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74 95% CI, 0.65 to 0.83 P<0.001). The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.Ī total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. Patients with elevated triglyceride levels are at increased risk for ischemic events. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |